50 year old female patient diagnosed in 2020 with seropositive rheumatoid arhrtitis with treatment 10mg per week methotrexate, developed crioglobulinemic vasculitis with skin, articular and renal involvement with treatment of cyclofosfamide 4 doses, hidroxicloroquine 400mg per day, and medrol 8mg per day. She has a normal articular exam at this consult. Should methotrexate be stopped or continued if she has treatment with cyclophosphamide?
Reading File
Finding Sources
Finding Sources
Searching PubMed
cryoglobulinemic vasculitis AND rheumatoid arthritis AND treatment
Searching PubMed
methotrexate AND cyclophosphamide AND vasculitis combination
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
cryoglobulinemic vasculitis non-HCV rheumatoid arthritis management
Reading File
Finding Sources
Searching PubMed
cryoglobulinemia vasculitis non-infectious immunosuppression treatment
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Searching the Web
methotrexate cyclophosphamide combination vasculitis rheumatoid safety continue stop
I now have sufficient information to provide a thorough, evidence-based answer. Let me compile the response.
This is a complex clinical scenario involving overlapping indications for immunosuppression. Here is a detailed analysis:
Clinical Context
This patient has:
- Seropositive RA (since 2020) on methotrexate (MTX) 10 mg/week
- Newly developed cryoglobulinemic vasculitis (CV) with skin, articular, and renal involvement - indicating a severe/organ-threatening presentation
- Current CV regimen: cyclophosphamide (4 doses), hydroxychloroquine 400 mg/day, methylprednisolone 8 mg/day
- Normal articular exam at this visit (RA is clinically controlled)
Should Methotrexate Be Continued or Stopped During Cyclophosphamide?
The short answer: MTX should be held (temporarily suspended) during active cyclophosphamide induction.
Rationale
1. Additive Myelosuppression - the Primary Concern
Both MTX and cyclophosphamide are cytotoxic/antiproliferative agents that suppress bone marrow. Cyclophosphamide - even at pulse/IV doses (4 doses) - causes leukopenia, neutropenia, and thrombocytopenia. MTX at even low weekly doses (7.5-20 mg/week) also suppresses the marrow and can lower the WBC count. Running them concurrently significantly amplifies the risk of:
- Severe leukopenia/neutropenia
- Life-threatening opportunistic infections (PCP pneumonia, fungal infections)
- Prolonged cytopenia requiring hospitalization
The Hopkins Vasculitis Center explicitly states that if WBC drops below 4,000/mm³ on MTX, MTX must be stopped, and this threshold is far more easily reached when cyclophosphamide is also being used. - Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 1230
2. MTX is Used as a Less Intensive Alternative to Cyclophosphamide - Not a Companion
The medical literature positions these as drugs on a severity spectrum, not as drugs routinely combined. In rheumatoid vasculitis specifically, the Mayo Clinic cohort (86 patients, 2000-2010) showed that:
- 29% received cyclophosphamide
- 55% received another DMARD (MTX, azathioprine, mycophenolate, hydroxychloroquine)
These groups overlapped but the standard practice is to use them sequentially, not simultaneously: cyclophosphamide for induction of severe disease, followed by a less toxic DMARD (MTX, azathioprine, or mycophenolate) for maintenance. - Henry's Clinical Diagnosis and Management, p. 1529-1531
The Rheumatology textbook (Elsevier 2022) states directly: "Antimetabolites such as mycophenolate mofetil or methotrexate... are reported to be effective" as alternatives after cyclophosphamide-based induction - not concurrent additions. - Rheumatology, 2-Volume Set, p. 332-335
3. The Role of MTX for this Patient's RA at This Moment
Her articular exam is normal at this visit. This means:
- The RA is clinically quiescent, likely aided by the corticosteroids she is already on (methylprednisolone 8 mg/day)
- The primary active problem is the cryoglobulinemic vasculitis, not her joint disease
- Continuing MTX for RA control is not urgently necessary while she is on systemic steroids and cyclophosphamide
Hydroxychloroquine, which she is already receiving (400 mg/day), also provides background RA disease modification and is notably protective - hydroxychloroquine is associated with lower odds of developing rheumatoid vasculitis and can help maintain RA control in the interim. - Henry's Clinical Diagnosis and Management, p. 1529
4. MTX and Renal Involvement - Additional Caution
This patient has renal involvement from cryoglobulinemic vasculitis. MTX is primarily renally cleared, and even mild reduction in GFR dramatically increases MTX toxicity (mucositis, cytopenias, nephrotoxicity). The Hopkins Vasculitis Center guidance states MTX "should be prescribed with caution or avoided in vasculitis patients with impaired renal function." This is an independent, strong reason to hold MTX until renal function stabilizes.
Proposed Management Strategy
| Phase | Action |
|---|---|
| During cyclophosphamide induction (current) | Hold MTX. Continue hydroxychloroquine 400 mg/day + methylprednisolone 8 mg/day |
| After completing 4 cyclophosphamide doses | Monitor CBC, renal function, cryoglobulins, complement (C3/C4), clinical response |
| Maintenance phase (if CV responds) | MTX can be reintroduced at a low dose (7.5-10 mg/week) once cyclophosphamide is complete, renal function is stable, and CBC has recovered - serving dual purpose as RA maintenance AND vasculitis relapse prevention |
| If CV is severe/refractory | Consider rituximab instead (superior evidence in CV; also controls seropositive RA) |
A Note on Rituximab
The Rheumatology textbook (Elsevier 2022) and Harrison's 22E both highlight that rituximab has the best evidence base for cryoglobulinemic vasculitis in the severe/moderate range (70-80% response rate in controlled trials). Rituximab also controls seropositive RA excellently and would eliminate the need for both MTX and cyclophosphamide going forward. This should be discussed with the treating team as a potential consolidation strategy.
Summary
Hold methotrexate during cyclophosphamide induction. The reasons are: (1) additive myelosuppression and infection risk, (2) the RA is clinically controlled on current steroids/hydroxychloroquine making MTX non-urgent, (3) renal involvement from the vasculitis increases MTX toxicity risk significantly, and (4) standard practice positions these agents as sequential (cyclophosphamide induction → DMARD maintenance), not concurrent. MTX can be reintroduced in the maintenance phase once cyclophosphamide is complete and renal function is confirmed stable. Rituximab is worth considering as a unifying therapy for both conditions.
This is a shared conversation. Sign in to Orris to start your own chat.